Sangamo Therapeutics (NASDAQ:SGMO) Issues Earnings Results

Sangamo Therapeutics (NASDAQ:SGMO) announced its earnings results on Monday. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02), Zacks reports. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%.

Sangamo Therapeutics Stock Performance

Sangamo Therapeutics stock traded up $0.05 during trading on Monday, reaching $0.75. The company had a trading volume of 4,628,475 shares, compared to its average volume of 8,623,031. Sangamo Therapeutics has a 12-month low of $0.30 and a 12-month high of $3.18. The stock’s 50 day moving average price is $0.78 and its two-hundred day moving average price is $1.36. The firm has a market capitalization of $171.89 million, a price-to-earnings ratio of -1.00 and a beta of 1.46.

Analyst Ratings Changes

SGMO has been the subject of a number of recent research reports. Royal Bank of Canada reiterated a “sector perform” rating and set a $2.00 price target on shares of Sangamo Therapeutics in a report on Tuesday, March 18th. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Sangamo Therapeutics in a report on Monday, April 7th. Finally, Truist Financial lowered their price target on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating for the company in a report on Thursday, January 23rd. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, Sangamo Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $5.17.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.